Stock market today: S&P 500 hits fresh record close on stronger economic growth
LONDON - Haleon plc (LSE/NYSE: HLN), a global leader in consumer health, has announced the purchase of 44,155,844 of its ordinary shares from Pfizer Inc. (NYSE:PFE) at a price of £3.85 per share, totaling approximately £170 million. This transaction, which took place off-market, is part of Haleon’s £500 million share buyback program for 2025 and follows the company’s previous announcement on February 27, 2025.
The shares acquired from Pfizer will be cancelled, reducing Pfizer’s interest in Haleon from approximately 7.3% to nil. This marks a significant shift in Haleon’s shareholder structure, as Pfizer had held a 32% stake at the time of Haleon’s demerger in July 2022.
Brian McNamara, CEO of Haleon, stated that this move aligns with the company’s disciplined capital allocation priorities and supports their commitment to delivering attractive returns for shareholders. He emphasized Haleon’s strong financial position and readiness to capitalize on future opportunities.
The completion of this share purchase from Pfizer, alongside Pfizer’s own offering to institutional investors, signifies Pfizer’s full exit from its investment in Haleon. The company will make an additional announcement once the off-market purchase is finalized.
Haleon’s portfolio includes well-known brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, spanning across major health categories like Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements (VMS).
This information is based on a press release statement from Haleon plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.